Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of icaritin versus Huachansu in biomarker-positive unresectable hepatocellular carcinoma
ChiCTR2200062675Phase 3Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Icaritin and cinobufacini in hepatocellular carcinoma (HCC) (2 arms), sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Overall survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
Icaritincinobufacini
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200062675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062675.